David Matly compensation by year
Inhibrx Biosciences Summary Compensation Table · the one fiscal year held| Component | FY2025 |
|---|---|
| Salary | $589,170 |
| Bonus | $0 |
| Stock awards | $0 |
| Option awards | $524,285 |
| Non-equity incentive | $304,985 |
| Pension and deferred compensation | $0 |
| All other | $17,500 |
| Total | $1,435,940 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Inhibrx Biosciences, Inc. DEF 14A filed April 23, 2026, accession 0002007919-26-000014, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Inhibrx Biosciences, Inc. filed document, accession 0002007919-26-000014. Every figure is read from that document and cited to the page and table it appears in. Filed April 23, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 50,000 | — | $14.05 |
| Option | 105,729 | — | $15.86 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Inhibrx Biosciences, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
1 Form 4 line since the FY2025 proxy (filed April 23, 2026)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-04-24 | Grant or award derivative | — | 50,000 | $0.00 | 50,000 |
The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Inhibrx Biosciences’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Lappe | Chief Executive Officer and Chairman of the Board of Directors | $2,892,473 |
| David Matly · this page | President | $1,435,940 |
| Kelly Deck | Chief Financial Officer | $923,696 |
David Matly's compensation dossier, Inhibrx Biosciences
You have read David Matly's totals and holdings. The dossier adds each equity grant Inhibrx Biosciences disclosed for David Matly and Inhibrx Biosciences's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full Inhibrx Biosciences compensation record
free company briefThis page is one person within Inhibrx Biosciences's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Inhibrx Biosciences's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Inhibrx Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order INBX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.